Juniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary Event

BOSTON, March 29, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced that it has been recognized as one of greater Boston's 15 companies with the most diverse boards, the GK15.  The Company accepted the award at the Get Konnected! 9^th Anniversary professional networking event on Tuesday, March 28 in Boston.  

"Not only is our Board of Directors accomplished and highly qualified in providing strategic guidance as we build a pipeline of women's health therapeutics, the diversity of membership seen on our Board is reflective of the real world," said Alicia Secor, Juniper's Chief Executive Officer.

"Diversity is of crucial importance to our corporate culture, and evidence supports that having a balanced and diverse Board is associated with increased innovation, competitiveness and sustainable growth, not to mention a more prosperous and inclusive workplace."

In addition to honoring members of the GK15, the event included a panel discussion and a fireside chat on gender and racially diverse corporate boards.

About Juniper Pharmaceuticals   
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the Crinone^® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone^® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.  
Follow us on LinkedIn  

Forward Looking Statements  
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Juniper's ability to leverage the 505(b)(2) pathway for its product candidates and the expectation that Juniper's core operating business will enable targeted product development investments. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. 

Media Contact:   
Amy Raskopf 
Director, Corporate Communications, Juniper Pharmaceuticals, Inc. 
917-673-5775 / [email protected]

Investor Contact:   
Laura Perry 
Argot Partners 
212-600-1902 / [email protected]

Heather Savelle 
Argot Partners 
212-600-1902 / [email protected]

SOURCE Juniper Pharmaceuticals, Inc.

Related Links

http://www.juniperpharma.com